Do you want to read an article? Please log in or register.
Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention
Heart, Artery and Coronary Diseases
Related content
Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation.
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group
doi: 10.1161/CIRCULATIONAHA.
RECOMMENDED
Further Publications
New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Atherosclerosis
Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgözoğlu L, Bonaca MP
doi: 10.1016/j.atherosclerosis.2020.12.013
Lipid-Lowering Drugs
A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention
JAMA Cardiol.
Thanassoulis G, Sniderman AD, Pencina MJ
doi: 10.1001/jamacardio.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines
JAMA.
Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ
doi: 10.1001/jama.2017.3416.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Cochrane Database Syst Rev
Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP
doi: 10.1002/14651858.CD011748.pub3
RECOMMENDED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Recommendations and Associated Levels of Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: A Comparison at Population Level of the American Heart Association/American College of Cardiology/Multisociety, US Preventive Services Task Force, Department of Veterans Affairs/Department of Defense, Canadian Cardiovascular Society, and European Society of Cardiology/European Atherosclerosis Society Clinical Practice Guidelines
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circ Cardiovasc Qual Outcomes
Pavlović J, Greenland P, Franco OH, Kavousi M, Ikram MK, Deckers JW, Ikram MA, Leening MJG
doi: 10.1161/CIRCOUTCOMES.120.007183
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Eur Heart J.
Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S
doi: 10.1093/eurheartj/ehx566.
Cardiovascular Risk and DiseasesHypertensionLipid-Lowering Drugs
Outcomes of an integrated community-based nurse-led cardiovascular disease prevention programme
Heart.
Connolly SB, Kotseva K, Jennings C, Atrey A, Jones J, Brown A, Bassett P, Wood DA
doi: 10.1136/heartjnl-
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention
doi: 10.1371/journal.pone.0211464.